Cargando…
Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan
BACKGROUND: Burden of aspergillosis is reported to be significant from developing countries including those in South Asia. The estimated burden in Pakistan is also high on the background of tuberculosis and chronic lung diseases. There is concern for management of aspergillosis with the emergence of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216335/ https://www.ncbi.nlm.nih.gov/pubmed/32393344 http://dx.doi.org/10.1186/s13756-020-00731-8 |
_version_ | 1783532393566568448 |
---|---|
author | Moin, Safia Farooqi, Joveria Jabeen, Kauser Laiq, Sidra Zafar, Afia |
author_facet | Moin, Safia Farooqi, Joveria Jabeen, Kauser Laiq, Sidra Zafar, Afia |
author_sort | Moin, Safia |
collection | PubMed |
description | BACKGROUND: Burden of aspergillosis is reported to be significant from developing countries including those in South Asia. The estimated burden in Pakistan is also high on the background of tuberculosis and chronic lung diseases. There is concern for management of aspergillosis with the emergence of azole resistant Aspergillus species in neighbouring countries in Central and South Asia. Hence the aim of this study was to screen significant Aspergillus species isolates at the Microbiology Section of Aga Khan Clinical Laboratories, Pakistan, for triazole resistance. METHODS: A descriptive cross-sectional study, conducted at the Aga Khan University Laboratories, Karachi, from September 2016–May 2019. One hundred and fourteen, clinically significant Aspergillus isolates [A. fumigatus (38; 33.3%), A. flavus (64; 56.1%), A. niger (9; 7.9%) A. terreus (3; 2.6%)] were included. The clinical spectrum ranged from invasive aspergillosis (IA) (n = 25; 21.9%), chronic pulmonary aspergillosis (CPA) (n = 58; 50.9%), allergic bronchopulmonary aspergillosis (ABPA) (n = 4; 3.5%), severe asthma with fungal sensitization (SAFS) (n = 4; 3.5%), saprophytic tracheobronchial aspergillosis (n = 23; 20.2%). Screening for triazole resistance was performed by antifungal agar screening method. The minimum inhibitory concentration (MIC) of 41 representative isolates were tested and interpreted according to the Clinical and Laboratory Standards Institute broth microdilution method. RESULTS: All the isolates were triazole-susceptible on agar screening. MICs of three azole antifungals for 41 tested isolates were found to be ≤1 ml/L; all isolates tested were categorized as triazole-susceptible, including 4 isolates from patients previously on triazole therapy for more than 2 weeks. The minimum inhibitory concentration required to inhibit the growth of 90% organisms (MIC(90)) of itraconazole, voriconazole and posaconazole of the representative Aspergillus isolates was 1 mg/L, 1 mg/L and 0.5 mg/L, respectively. CONCLUSION: Triazole resistance could not be detected amongst clinical Aspergillus isolates from the South of Pakistan. However, environmental strains remain to be tested for a holistic assessment of the situation. This study will set precedence for future periodic antifungal resistance surveillance in our region on Aspergillus isolates. |
format | Online Article Text |
id | pubmed-7216335 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72163352020-05-18 Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan Moin, Safia Farooqi, Joveria Jabeen, Kauser Laiq, Sidra Zafar, Afia Antimicrob Resist Infect Control Research BACKGROUND: Burden of aspergillosis is reported to be significant from developing countries including those in South Asia. The estimated burden in Pakistan is also high on the background of tuberculosis and chronic lung diseases. There is concern for management of aspergillosis with the emergence of azole resistant Aspergillus species in neighbouring countries in Central and South Asia. Hence the aim of this study was to screen significant Aspergillus species isolates at the Microbiology Section of Aga Khan Clinical Laboratories, Pakistan, for triazole resistance. METHODS: A descriptive cross-sectional study, conducted at the Aga Khan University Laboratories, Karachi, from September 2016–May 2019. One hundred and fourteen, clinically significant Aspergillus isolates [A. fumigatus (38; 33.3%), A. flavus (64; 56.1%), A. niger (9; 7.9%) A. terreus (3; 2.6%)] were included. The clinical spectrum ranged from invasive aspergillosis (IA) (n = 25; 21.9%), chronic pulmonary aspergillosis (CPA) (n = 58; 50.9%), allergic bronchopulmonary aspergillosis (ABPA) (n = 4; 3.5%), severe asthma with fungal sensitization (SAFS) (n = 4; 3.5%), saprophytic tracheobronchial aspergillosis (n = 23; 20.2%). Screening for triazole resistance was performed by antifungal agar screening method. The minimum inhibitory concentration (MIC) of 41 representative isolates were tested and interpreted according to the Clinical and Laboratory Standards Institute broth microdilution method. RESULTS: All the isolates were triazole-susceptible on agar screening. MICs of three azole antifungals for 41 tested isolates were found to be ≤1 ml/L; all isolates tested were categorized as triazole-susceptible, including 4 isolates from patients previously on triazole therapy for more than 2 weeks. The minimum inhibitory concentration required to inhibit the growth of 90% organisms (MIC(90)) of itraconazole, voriconazole and posaconazole of the representative Aspergillus isolates was 1 mg/L, 1 mg/L and 0.5 mg/L, respectively. CONCLUSION: Triazole resistance could not be detected amongst clinical Aspergillus isolates from the South of Pakistan. However, environmental strains remain to be tested for a holistic assessment of the situation. This study will set precedence for future periodic antifungal resistance surveillance in our region on Aspergillus isolates. BioMed Central 2020-05-11 /pmc/articles/PMC7216335/ /pubmed/32393344 http://dx.doi.org/10.1186/s13756-020-00731-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Moin, Safia Farooqi, Joveria Jabeen, Kauser Laiq, Sidra Zafar, Afia Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan |
title | Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan |
title_full | Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan |
title_fullStr | Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan |
title_full_unstemmed | Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan |
title_short | Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan |
title_sort | screening for triazole resistance in clinically significant aspergillus species; report from pakistan |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216335/ https://www.ncbi.nlm.nih.gov/pubmed/32393344 http://dx.doi.org/10.1186/s13756-020-00731-8 |
work_keys_str_mv | AT moinsafia screeningfortriazoleresistanceinclinicallysignificantaspergillusspeciesreportfrompakistan AT farooqijoveria screeningfortriazoleresistanceinclinicallysignificantaspergillusspeciesreportfrompakistan AT jabeenkauser screeningfortriazoleresistanceinclinicallysignificantaspergillusspeciesreportfrompakistan AT laiqsidra screeningfortriazoleresistanceinclinicallysignificantaspergillusspeciesreportfrompakistan AT zafarafia screeningfortriazoleresistanceinclinicallysignificantaspergillusspeciesreportfrompakistan |